- Details
- Alicia Morgans interviews Maria De Santis about three studies: the SunRISe-1 trial for non-muscle-invasive bladder cancer, the AMBASSADOR study on adjuvant pembrolizumab for muscle-invasive urothelial carcinoma, and the VOLGA trial exploring ctDNA clearance as a biomarker. Dr. De Santis highlights the promising results of TAR-200, a novel gemcitabine intravesical system, which shows high complete...
|
- Details
- Neeraj Agarwal interviews Marta Garcia de Herreros about presentation on tumor suppressor gene (TSG) signatures in metastatic hormone-sensitive prostate cancer (mHSPC). Dr. Garcia de Herreros discusses the TSG-low signature, based on low expression of RB1, PTEN, and TP53 genes, which predicts early progression to castration-resistant prostate cancer (CRPC) and the development of aggressive variant...
|
- Details
- Zachary Klaassen interviews Laurence Albiges about the CaboPoint Phase II Trial. Dr. Albiges discusses the evolving landscape of second-line treatment for clear cell renal cell carcinoma (RCC) after first-line immunotherapy combinations. The CaboPoint study evaluates cabozantinib as a pure second-line treatment in patients who have failed either nivolumab-ipilimumab or an IO-TKI strategy. Results...
|
- Details
- Zach Klaassen interviews Neal Shore about the EMBARK trial's post hoc analysis by age. The study examines the efficacy of enzalutamide alone or combined with leuprolide for high-risk biochemical recurrence in prostate cancer patients. Dr. Shore discusses the trial design, key results, and the implications of age stratification ( 70 years) on treatment outcomes and adverse events. The analysis show...
|
- Details
- Zach Klaassen interviews Joaquín Mateo about the ZZ-FIRST trial, which explores the combination of enzalutamide and talazoparib in metastatic hormone-naive prostate cancer. Dr. Mateo discusses the trial design, preliminary results, and the rationale behind combining AR-targeting agents with PARP inhibitors. The study shows promising results in terms of PSA complete response and early indications o...
|
- Details
- Ruchika Talwar interviews David Morris about changes to Medicare Part D resulting from the Inflation Reduction Act. Dr. Morris discusses how these changes benefit prostate cancer patients and other Medicare recipients by reducing out-of-pocket expenses for prescription drugs. Key points include the introduction of a $2,000 annual out-of-pocket maximum cap, the option for cost smoothing to spread p...
|
- Details
- Oliver Sartor interviews Chris Behrenbruch about radiopharmaceuticals in cancer treatment. Dr. Behrenbruch discusses his passion for nuclear medicine, emphasizing its multidisciplinary nature and potential for patient impact. They explore the complexities of isotope selection, particularly Lutetium-177 and Actinium-225, highlighting the importance of matching isotopes to specific biological proble...
|
- Details
- Oliver Sartor interviews Jessica Jensen about radiopharmaceuticals in cancer treatment. Ms. Jensen discusses her passion for the field, emphasizing the patient-centric approach and the immediate insights gained from molecular imaging. They explore the complexities of isotope selection, highlighting the importance of understanding tumor heterogeneity and target expression. Ms. Jensen stresses the n...
|
- Details
- Fred Saad discusses the ARANOTE phase 3 study results, evaluating darolutamide plus ADT in metastatic hormone-sensitive prostate cancer. The trial shows significant improvement in radiographic progression-free survival and secondary endpoints, including time to metastatic CRPC and pain progression. Dr. Saad emphasizes the favorable safety profile of darolutamide, with adverse events similar to pla...
|
- Details
- Cédric Pobel discusses an ancillary study of the PEACE-1 trial, focusing on phenotypic and genomic characterization of de novo metastatic prostate cancer. The study analyzes immunohistochemistry and genomic data from patient biopsies. Key findings include the identification of five phenotypes based on androgen receptor and neuroendocrine marker expression. Notably, about 25% of patients show neuro...
|
